Similarly, studies have reported that a combination-therapy of lapatinib and capecitabine was superior to capecitabine alone in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer [48,49], whereas erlotinib significantly improved the survival of patients with advanced pancreatic cancer receiving gemcitabine [50,51]. This evidence concerns the gene ERBB2 and pancreatic neoplasm.